Shionogi and Pfizer are now in commercial discussions after their antibiotics were recommended for use via the UK’s new subscription-style payment model, which will ensure a fixed annual fee is paid to companies regardless of how many prescriptions are issued. The UK is urging other countries to offer similar incentives to help beat global antimicrobial resistance.
Fetcroja (cefiderocol) and Zavicefta (ceftazidime–avibactam) could soon become the first antibiotics to be made available in England as part of an innovative subscription-style payment model that aims to incentivize the development of novel antimicrobials and tackle the problem of antimicrobial resistance (AMR).
The new UK payment model, the first of its kind in the world, will ensure that a fixed annual fee...
Create an account to read this article
Already a subscriber?
The UK drug regulator and England’s health technology assessment agency have joined forces under an information sharing agreement, aimed at accelerating patient access to newly approved medicines by three to six months.
Canadian politicians must “move quickly” to introduce policies that will speed up access to medicines, such as by broadening criteria for the temporary reimbursement of medicines, the Canadian Chamber of Commerce says.
Biogen has U-turned on its original decision not to file Qalsody for marketing approval in the UK for treating certain patients with amyotrophic lateral sclerosis. The move appears to have been triggered by a change in the reimbursement pathway agreed for the product.
Sam Roberts, chief executive of the health technology assessment institute, NICE, will step down from her role at the end of the year. The agency is now on the lookout for a new leader, who will be the fourth in its history.
A newly launched UK government inquiry is seeking to learn how viable it would be to bring back domestic control over the entire drug manufacturing pipeline.
Pfizer is in active discussions with Trump on MFN pricing and collaborating with peers on direct sales as an approach to lower drug prices, CEO Albert Bourla said.
The billionaire investor said during a recent conference that brand drug manufacturers want to work with his Cost Plus Drug Co., but are afraid the PBMs will retaliate.
